Posted 10/23/2016 5:45 PM (GMT 0)
Sallyy,
In the UK, Xtandi (enzalutamide), but not Zytiga (abiraterone), is approved for castration-resistant men who have not yet had chemotherapy. Castration-resistance means that PSA continues to rise while on first-line androgen deprivation therapy. In my opinion, Xtandi is a somewhat more effective hormonal drug.
Chemotherapy is a different decision. If the bone scan shows there are multiple metastases - 4 or more - at distant sites, Taxotere (docetaxel) has been shown to extend survival significantly.